Followers | 48 |
Posts | 1181 |
Boards Moderated | 0 |
Alias Born | 04/20/2018 |
![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Thursday, May 24, 2018 2:10:10 AM
I don't care if the stock price is $.02 or $.03 tomorrow or Friday. What I look at is how is the company being run, are they delivering on their stated objectives and what is the opportunity.
The key with CMTH/CELZ is patience!! It is going to take time (weeks/months) to get doctors signed, equipment delivered, training completed just to begin producing revenue. Customers have to be informed, procedures scheduled, etc., etc.,.
I am not expecting the next 10Q to have huge revenue because of the factors mentioned above. However, I expect as more Urologists/Practitioners are brought onboard and able to perform procedures and momentum builds through awareness, the revenue will begin to compound quickly. My expectation is their revenue will not start hitting it's stride until two to three quarters from now or six to nine months.
Then there will be serious momentum and I would expect a significant buyout offer to be considered by CMTH leadership. They may have an offer now, but with all the patents and just getting Caverstem to commercialization, I believe they wait, let revenue build and put themselves in a much better position to cash in for maximum return.
CMTH/CELZ leadership have shown so far to be smart, pragmatic and play chess with confidence. As ES pointed out, Ichim has been through buyouts multiple times before. He and Warbington know they will get top dollar once they have momentum and strong revenue. That gives them leverage on how they would want to structure any deal or decide not to sell.
If health insurance companies at some point begin paying for a portion of the cost of the procedure, then money will flow from the heavens. Even without insurance participation, there are millions of men who will spend the $3k+ if they know it will fix their issue. As a man, having the ability to perform on demand without the need to take pills, will be enough motivation to sign up for Caverstem procedure. Like others have mentioned their significant others will be pushing them to get the procedure done.
I think it's great they have a female handling social media outreach. Another small, but well thought out part of CMTH leaderships ongoing game of chess. These guys are the real deal.
Recent CELZ News
- Form 8-K - Current report • Edgar (US Regulatory) • 07/25/2024 08:10:25 PM
- Creative Medical Technology Holdings Initiates Development of AI-Driven Diagnostic and Treatment Program for Biologic and Chemical Exposure Utilizing its Validated iPSC Personalized Medicine Program • GlobeNewswire Inc. • 07/24/2024 01:00:39 PM
- Creative Medical Technology Holdings Provides Corporate Update • GlobeNewswire Inc. • 07/10/2024 12:30:00 PM
- Creative Medical Technology Holdings Announces Evolutionary Development of its iPSCelz® Program with the Successful Generation of iPSC Derived Islet Cells that Produce Human Insulin • GlobeNewswire Inc. • 06/24/2024 12:30:00 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 06/05/2024 08:05:11 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/17/2024 08:02:27 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 08:45:39 PM
- Creative Medical Technology Holdings Provides Corporate Update • Business Wire • 03/27/2024 01:00:00 PM
- Creative Medical Technology Holdings Inc. Announces FDA Authorization for Groundbreaking Type 1 Diabetes Prevention Therapy Under Expanded Access • Business Wire • 03/07/2024 02:15:00 PM
- Biotech Finds Mid-Week Success Following FDA Announcement • AllPennyStocks.com • 03/06/2024 09:10:00 PM
- Creative Medical Technology Holdings, Inc. Receives FDA Orphan Drug Designation for CELZ-101 in Key Transplantation Therapy • Business Wire • 03/06/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/20/2023 09:05:37 PM
- Creative Medical Technology Holdings Provides Corporate Update • PR Newswire (US) • 11/15/2023 01:00:00 PM
- Creative Medical Technology Holdings Announces IRB Approval for FDA Cleared Phase 1/2 Clinical Trial of StemSpine® using AlloStem™ ("CELZ-201-DDT") Novel Cell Therapy to Treat Chronic Lower Back Pain • PR Newswire (US) • 10/10/2023 12:00:00 PM
- Creative Medical Technology Holdings Receives FDA Clearance to Initiate a Phase 1/2 Clinical Trial of StemSpine® using AlloStem™ (CELZ-201-DDT) for the Treatment of Chronic Lower Back Pain • PR Newswire (US) • 09/19/2023 12:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/11/2023 08:45:38 PM
Glidelogic Corp. Announces Revolutionary AI-Generated Content Copyright Protection Solution • GDLG • Jul 26, 2024 12:30 PM
Southern Silver Files NI43-101 Technical Report for its Updated Preliminary Economic Assessment for the Cerro Las Minitas Project • SSV • Jul 25, 2024 8:00 AM
Greenlite Ventures Completes Agreement with No Limit Technology • GRNL • Jul 19, 2024 10:00 AM
VAYK Expects Revenue from First Airbnb Property Starting from August • VAYK • Jul 18, 2024 9:00 AM
North Bay Resources Acquires Mt. Vernon Gold Mine, Sierra County, California, with Assays up to 4.8 oz. Au per Ton • NBRI • Jul 18, 2024 9:00 AM
Nightfood Holdings Signs Letter of Intent for All-Stock Acquisition of CarryOutSupplies.com • NGTF • Jul 17, 2024 1:00 PM